Brenntag Introduces New Biopharma Brand

© Brenntag

The brand brings together a regulatory-ready portfolio that supports customers from early development through to commercial production. The solution designed specifically for biopharma companies to evolve their manufacturing process from transactional supplier relationships to a holistic, curated and compliant portfolio. This reduces complexity, accelerates timelines and ultimately brings effective therapies to patients faster.

The portfolio is backed by Brenntag's global distribution network, long-standing industry trust and extensive technical expertise, ensuring safe deliveries, consistent documentation and full regulatory compliance.

Byphar is designed to support innovators, emerging biotechnology companies, CDMOs, vaccine manufacturers, biosimilar manufacturers and diagnostics companies in a variety of manufacturing processes including mAbs, recombinant proteins, cell and gene therapies, vaccines, nucleic acid-based manufacturing and ADC production.

Gearoid O'Rourke, Senior Director Biopharma at Brenntag Pharma, explains: "Byphar represents a significant step forward in supporting our biopharma customers. By combining high quality raw materials and flexibility with global supply reliability and deep regulatory expertise, we help our customers accelerate development and ensure the highest standards at all stages of manufacturing."

The brand's raw materials are divided into three clearly defined categories, which will be available from July 2026. Each is tailored to specific risk levels and development phases:

• Byphar Explore NonGMP materials for early stage development, research and development and non-critical applications. Monograph compliant where applicable, with essential regulatory documents.
• Byphar Enhance GMP-compliant materials, suitable for all biopharmaceutical manufacturing phases, in accordance with IPEC and EXCiPACT guidelines and complete regulatory documentation.
• Byphar Excel LBLE-critical raw materials for high-risk applications, manufactured under GMP conditions, multicompendial where applicable, and supported by extensive regulatory documentation.

This structured approach enables customers to select the right grade of material for each stage of development, accelerating qualification and regulatory readiness. The portfolio also includes co-branded products produced in partnership with globally recognized manufacturers, ensuring exceptional purity, consistency and supply reliability. Byphar integrates the expertise of several long-standing industry leaders:

• Budenheim - High purity phosphates with rigorous impurity control and multi-pharmacopoeial compliance.
• Citribel - Sustainable, high-volume production of citric acid and citrates with over a century of manufacturing experience.
• K+S - Reliable, pharmaceutical-grade salts produced from proprietary NaCl and KCl resources.
• Kerry - High quality acetates manufactured to strict cGMP standards for critical biopharmaceutical applications.

These partnerships strengthen Byphar's ability to deliver consistent, regulatory compliant materials worldwide.